The main objective of this study was to determine the feasibility and the antitumor activity of a chemotherapy regimen with a 48-hour infusion of 5-fluorouracil (5-FU), leucovorin (LV), cisplatin (CDDP), and epirubicin (EPIDX) administered every 3 weeks in patients with locally advanced or metastatic gastric cancer. Thirty-three patients received CDDP 60 mg/m2 over 30 minutes followed by 1-LV 250 mg/m2 over 2 hours followed by EPIDX 60 mg/m2 over 5 minutes (bolus) and followed by 5-FU 3,800 mg/m2 as a 48-hour semiintermittent continuous infusion, with 67% of total daily dose administered between 4 pm and midnight. Four patients had a locally advanced disease and 29 had metastatic disease. A total of 171 cycles were administered. Most relevant toxicities were stomatitis (grade III in 2% of cycles and 12% of patients) and neutropenia (grade III-IV in 8% of cycles and 28% of patients) with 3 (9%) patients experiencing 1 episode of febrile neutropenia. No toxic deaths occurred. Thirty-one patients were evaluable for response. In 3 patients (9.6%) a complete response and in 11 patients (35.4%) a partial response was observed, for an objective response rate of 45% (95% C.I. 27-64%). Median progression-free and overall survival were 5.9 and 9.8 months, respectively. In conclusion, this regimen is feasible in an outpatient setting with acceptable and manageable toxicities, and it is associated with promising antitumor activity, time to progression, and survival.
|Data di pubblicazione:||2004|
|Titolo:||5-fluorouracil administered as a 48-hour semi-intermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients|
|Autore/i:||Allegrini, G; Falcone, A; DI MARSICO, R; Lencioni, M; Masi, G; Galli, C; Cupini, S; Pfanner, E; Marcucci, L; Conte, Pierfranco|
|Codice identificativo ISI:||WOS:000188783600018|
|Codice identificativo Scopus:||2-s2.0-10744226120|
|Codice identificativo Pubmed:||14758142|
|Citazione:||5-fluorouracil administered as a 48-hour semi-intermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients / Allegrini, G; Falcone, A; DI MARSICO, R; Lencioni, M; Masi, G; Galli, C; Cupini, S; Pfanner, E; Marcucci, L; Conte, Pierfranco. - In: AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS. - ISSN 0277-3732. - STAMPA. - 27(2004), pp. 101-105.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris